These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38776391)

  • 1. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6.
    Stadler CR; Ellinghaus U; Fischer L; Bähr-Mahmud H; Rao M; Lindemann C; Chaturvedi A; Scharf C; Biermann I; Hebich B; Malz A; Beresin G; Falck G; Häcker A; Houben A; Erdeljan M; Wolf K; Kullmann M; Chang P; Türeci Ö; Şahin U
    Sci Transl Med; 2024 May; 16(748):eadl2720. PubMed ID: 38776391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
    Seckinger A; Delgado JA; Moser S; Moreno L; Neuber B; Grab A; Lipp S; Merino J; Prosper F; Emde M; Delon C; Latzko M; Gianotti R; Lüoend R; Murr R; Hosse RJ; Harnisch LJ; Bacac M; Fauti T; Klein C; Zabaleta A; Hillengass J; Cavalcanti-Adam EA; Ho AD; Hundemer M; San Miguel JF; Strein K; Umaña P; Hose D; Paiva B; Vu MD
    Cancer Cell; 2017 Mar; 31(3):396-410. PubMed ID: 28262554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL.
    Malik-Chaudhry HK; Prabhakar K; Ugamraj HS; Boudreau AA; Buelow B; Dang K; Davison LM; Harris KE; Jorgensen B; Ogana H; Pham D; Schellenberger U; Van Schooten W; Buelow R; Iyer S; Trinklein ND; Rangaswamy US
    MAbs; 2021; 13(1):1890411. PubMed ID: 33818299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
    Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
    Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
    Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
    Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6.
    Stadler CR; Bähr-Mahmud H; Plum LM; Schmoldt K; Kölsch AC; Türeci Ö; Sahin U
    Oncoimmunology; 2016 Mar; 5(3):e1091555. PubMed ID: 27141353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of anti-CD79b/CD3 bispecific antibody, a potential therapy for B cell malignancies.
    Wang J; Li C; He K; Kuang Z; Lu J; Yao Y; He F; Li N; Li L; Fu F; Wu Z; Zhou S; Kang D; Qiu X; Wu M; Liu Y; Cao X; Xu M; Chen B; Wu W; Guo F
    Cancer Immunol Immunother; 2023 Feb; 72(2):493-507. PubMed ID: 35963895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.
    Smith EJ; Olson K; Haber LJ; Varghese B; Duramad P; Tustian AD; Oyejide A; Kirshner JR; Canova L; Menon J; Principio J; MacDonald D; Kantrowitz J; Papadopoulos N; Stahl N; Yancopoulos GD; Thurston G; Davis S
    Sci Rep; 2015 Dec; 5():17943. PubMed ID: 26659273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer.
    Crawford A; Haber L; Kelly MP; Vazzana K; Canova L; Ram P; Pawashe A; Finney J; Jalal S; Chiu D; Colleton CA; Garnova E; Makonnen S; Hickey C; Krueger P; DelFino F; Potocky T; Kuhnert J; Godin S; Retter MW; Duramad P; MacDonald D; Olson WC; Fairhurst J; Huang T; Martin J; Lin JC; Smith E; Thurston G; Kirshner JR
    Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical characterization of a Fab-like CD3/CLDN18.2 XFab® bispecific antibody against solid tumors.
    Xu G; Qian N; Liu Y; Li H; Yang C; Wang J; Wang F; Chen L; Bai G; Xu Q; Pan X; Gao X
    Immunobiology; 2022 Nov; 227(6):152283. PubMed ID: 36198215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered mRNA-expressed bispecific antibody prevent intestinal cancer via lipid nanoparticle delivery.
    Wu L; Wang W; Tian J; Qi C; Cai Z; Yan W; Xuan S; Shang A
    Bioengineered; 2021 Dec; 12(2):12383-12393. PubMed ID: 34895063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
    Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
    Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
    MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies.
    Liu L; Lam CK; Long V; Widjaja L; Yang Y; Li H; Jin L; Burke S; Gorlatov S; Brown J; Alderson R; Lewis MD; Nordstrom JL; Koenig S; Moore PA; Johnson S; Bonvini E
    Clin Cancer Res; 2017 Mar; 23(6):1506-1518. PubMed ID: 27663593
    [No Abstract]   [Full Text] [Related]  

  • 17. A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART
    Betts A; Haddish-Berhane N; Shah DK; van der Graaf PH; Barletta F; King L; Clark T; Kamperschroer C; Root A; Hooper A; Chen X
    AAPS J; 2019 May; 21(4):66. PubMed ID: 31119428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
    de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
    Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
    de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
    Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.